AstraZeneca Taps Pieris For Inhaled Asthma Anticalins

 
• By Alexandra Shimmings

AstraZeneca is to pay $57.5m to get its hands on biotech Pieris Pharmaceuticals' Anticalin technology to bolster its early stage respiratory portfolio, with a lead product candidate already being prepared for Phase I.

Chickadee
A Drug Candidate In The Clinic Worth Two In The Lab? • Source: Shutterstock

More from Business

More from Scrip